Inhibitors in young boys with haemophilia

Bailliere's Best Practice and Research in Clinical Haematology

Volumn 13, Issue 3, 2000, Pages 457-468

  Lusher, Jeanne M ^a  

^a CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

Author keywords

Activated prothrombin complex concentrates; Factor IX inhibitors; Factor VIII inhibitors; Haemophilia; Immune tolerance regimen; Porcine factor VIII; RF VIIa

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; ANTIHISTAMINIC AGENT; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 DERIVATIVE; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 9; BUFFER; CYCLOPHOSPHAMIDE; HLA ANTIGEN; HYDROCORTISONE; IMIDAZOLE; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9; VON WILLEBRAND FACTOR;

ALLERGIC REACTION; ANAPHYLAXIS; ANIMAL CELL; ANTIBODY TITER; ARTICLE; BLEEDING; CHILD; CHILD CARE; CHILDHOOD DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG ACTIVITY; DRUG HALF LIFE; FAMILY COUNSELING; GENETIC RISK; HEALTH CARE COST; HEMOPHILIA A; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; INCIDENCE; MALE; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0033692789     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1053/beha.2000.0088     Document Type: Article

References (80)

1. Acquired circulating anticoagulants in hemophilia
2. Prevalence of inhibitors in hemophilia A and B
3. Incidence of inhibitors in hemophilia A patients - A review of recent studies of recombinant and plasma-derived factor VIII concentrates
4. Incidence of factor VIII and factor IX inhibitors in haemophiliacs
5. Recombinant F VIII (Kogenate) treatment of previously untreated patients (PUPs) with hemophilia A: Update of safety, efficacy and inhibitor development after seven study years
6. Safety and immunogenicity of recombinant factor VIII (Recombinate®) in previously untreated patients (PUPs): A 6.5 year update
7. French previously untreated patients with severe hemophilia A after exposure to recombinant factor VIII: Incidence of inhibitor and evaluation of immune tolerance
8. Transient inhibitors in patients with hemophilia A
9. Safety, efficacy, and inhibitor development in previously untreated patients (PUPs) treated exclusively with B-domain deleted recombinant F VIII (BDD rF VIII)
10. Haemophilia A: Mutation type determines risk of inhibitor formation
11. Inhibitor development in haemophilia A patients with inversion of the Intron 22 of the factor VIII gene
12. Frequency of inhibitor development in haemophiliacs treated with low purity factor VIII
13. HLA class II profile: A determinant of inhibitor development in severe haemophilia A
14. Relationship of major histocompatibility complex class II genes to inhibitor formation in haemophilia A
15. Factor VIII inhibitors in mild and moderate severity haemophilia A
16. A higher than expected incidence of factor VIII inhibitors in multi-transfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate
17. Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate
18. A more uniform measurement of factor VIII inhibitors
19. The Nijmegen modification of the Bethesda assay for factor VIII inhibitors: Improved specificity and reliability
20. The design and analysis of half-life and recovery studies for Factor VIII and Factor IX
21. A two-phase linear regression model for biological half-life data
22. Laboratory tests for factor VIII inhibitors, their variation, significance and interpretation
23. Laboratory diagnosis of factor VIII inhibitors
24. Induced immunotolerance for factor VIII inhibitor patients
25. Induction of immune tolerance in haemophilia A inhibitor patients by the 'Bonn protocol': Predictive parameter for therapy duration and outcome
26. Induction of immune tolerance to factor VIII in hemophiliacs with inhibitors
27. Disappearance of factor VIII:C antibodies in patients with haemophilia A upon frequent administration of factor VIII in intermediate low dose
28. Low dose immune tolerance induction in hemophilia A patients with inhibitors
29. Induction of immune tolerance in patients with hemophilia A and inhibitors
30. Immune tolerance therapy in paediatric haemophiliacs with factor VIII inhibitors: 14 years follow-up
31. Immune tolerance induction in the treatment of paediatric haemophilia A patients with factor VIII inhibitors
32. Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide and factor VIII
33. Extracorporeal immunoadsorption for the treatment of haemophilia patients with inhibitors to factor VIII or IX
34. International immune tolerance registry, 1997 update
35. Analysis of the North American Immune Tolerance Registry (NAITR) 1993-1997: Current practice implications
36. The German national immune tolerance registry, 1997 update
37. Comparison of the International Immune Tolerance registry and the North American Immune Tolerance Registry
38. Immune tolerance: A synopsis of the international experience
39. Personal communication
40. Activated prothrombin complex concentrates for persons with factor VIII inhibitors
41. Acute myocardial infarction during management with an activated prothrombin complex concentrate in a person with factor VIII deficiency and factor VIII inhibitor
42. Thrombogenicity associated with factor IX complex concentrates
43. The use of agents that by-pass factor VIII inhibitors in patients with haemophilia
44. Von Willebrand factor contaminating porcine factor VIII concentrate causes platelet aggregation
45. The clinical use of porcine factor VIII
46. Clinical experience with polyelectrolyte-fractionated porcine factor VIII concentrate in the treatment of hemophiliacs with antibodies to factor VIII
47. Use of porcine F VIII for surgical procedures in hemophilia A patients with inhibitors
48. Induction of immune tolerance in patients with haemophilia A and inhibitors treated with porcine F VIII by home therapy
49. The use of porcine F VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII:C: A multicenter U.S. trial
50. Porcine factor VIII: Continuous infusion, immune tolerance induction and prophylaxis
51. Clinical experience with human plasma-derived factor VIIa in patients with hemophilia A and high titer inhibitors
52. Recombinant activated factor VII in the treatment of bleeding episodes in patients with inherited and acquired bleeding disorders
53. Successful use of recombinant factor VIIa in patient with severe hemophilia A during synovectomy
54. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa
55. A randomimzed double-blind comparison of two dosage levels of recombinant Factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with hemophilia A and B with and without inhibitors
56. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novo Seven) in haemophiliacs with inhibitor
57. Use of NovoSeven® as first line therapy for bleeding episodes in hemophiliacs with factor VII or IX inhibitors (Nosepac study)
58. Prospective, randomized trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery
59. Treatment of acute bleeding episodes with rF VIIa
60. Management of hemophilia patients with inhibitors
61. Clinical experience with recombinant factor VIIa: A review
62. Experience with recombinant factor VIIa in an infant hemophiliac with inhibitors to F VII undergoing emergency central line placement
63. Recombinant activated VII (rF VIIa) therapy for intercranial hemorrhage in hemophilia A patients with inhibitors
64. Clinical experience with activated factor VII: Focus on safety aspects
65. Use of recombinant activated factor VII for treatment of retropharyngeal hemorrhage in a hemophilic patient with high titer inhibitor
66. Fessability of using recombinant factor VIIa in continuous infusion
67. Experience with continuous infusion of recombinant activated factor VII
68. Acute hemarthroses: The benefits of early versus late treatment with recombinant factor VIIa
69. Early treatment with recombinant factor VIIa results in greater efficacy with less product
70. Efficacy, safety and treatment cost considerations
71. Pharmaco-economic aspects of inhibitor treatment
72. Treatment of patients with inhibitors: Cost issues
73. Molecular structure, epitopes and mutations associated with inhibitor formation
74. Anaphylactic response to factor IX replacement therapy in haemophilia B patients: Complete gene deletions confer the highest risk
75. Gene deletions of patients with haemophilia B and anti-factor VIII antibodies
76. Factor IX inhibitors and anaphylaxis in hemophilia B
77. Management of haemophilia B patients with inhibitor and anaphylaxis
78. Nephrotic syndrome as a complication of immune tolerance in hemophilia B
79. Inhibitor to F IX in haemophilia B and nephrotic syndrome in the course of immune tolerance treatment
80. Myocardial infarction after FEIBA therapy in a patient with a factor IX inhibitor